Met Life Investment Management, LLC Syndax Pharmaceuticals Inc Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 50,515 shares of SNDX stock, worth $827,435. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,515
Previous 47,554
6.23%
Holding current value
$827,435
Previous $915,000
27.1%
% of portfolio
0.0%
Previous 0.01%
Shares
33 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$140 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$130 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$97.5 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$87 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$80 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $927M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...